Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody
NCT ID: NCT03282435
Last Updated: 2017-09-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
30 participants
INTERVENTIONAL
2018-01-31
2023-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CAR-T Cell Immunotherapy for Advanced Lung Cancer
NCT03330834
A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status
NCT07034391
PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer
NCT05325684
LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
NCT05886439
Preconditioning Chemotherapy Combination With Cytokine Induced Killer Cell (CIK) Immunotherapy
NCT01902875
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CIK cells with PD-1 blocking
CIK cellular therapy with PD-1 blocking combined with standard lung cancer treatment
CIK cells with PD-1 blocking
CIK cellular therapy with PD-1 blocking
standard lung cancer treament
standard non-small cell lung cancer treatment: surgery, chemotherapy
CIK cells without PD-1 blocking
CIK cellular therapy without PD-1 blocking combined with the same standard lung cancer treatment as the experimental group patients receive
standard lung cancer treament
standard non-small cell lung cancer treatment: surgery, chemotherapy
CIK cells without PD-1 blocking
CIK cellular therapy without PD-1 blocking
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CIK cells with PD-1 blocking
CIK cellular therapy with PD-1 blocking
standard lung cancer treament
standard non-small cell lung cancer treatment: surgery, chemotherapy
CIK cells without PD-1 blocking
CIK cellular therapy without PD-1 blocking
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* more than 50% tumor tissues positive with PD-L1;
* EGFR and ALK wild type
* no other tumors
Exclusion Criteria
40 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dalian University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
xiaolin Yuan
Role: PRINCIPAL_INVESTIGATOR
Affiliated Zhongshan Hospital of Dalian University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
zsyy_zxsys2018-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.